Role of Pharmacogenetic Testing in the Risk and Safety Assessment of Valproates: The Ethnic Aspect (Review)

Role of Pharmacogenetic Testing in the Risk and Safety Assessment of Valproates: The Ethnic Aspect (Review)

INTRODUCTION. Pharmacogenetic (PGx) testing plays a significant role in predicting the risk of adverse drug reactions (ADRs) associated with valproic acid (VPA) products, which are among the most prescribed medicinal products in neurology and psychiatry. However, the sensitivity and specificity of P...

Full description

Saved in:

Bibliographic Details
Main Authors:	N. A. Shnayder, V. V. Grechkina, V. V. Arkhipov, R. F. Nasyrova
Format:	Article
Language:	Russian
Published:	Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2024-07-01
Series:	Безопасность и риск фармакотерапии
Subjects:	valproic acid valproate-induced adverse reactions ethnicity genetic polymorphisms allelic variants cytochrome p450 pharmacogenetic testing pharmacogenetic panel personalised medicine
Online Access:	https://www.risksafety.ru/jour/article/view/423
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population
by: K. B. Mirzaev, et al.
Published: (2019-07-01)

Genetic features of a patient may influence the efficacy and safety profile of a medicinal product
by: D. A. Sychev
Published: (2024-07-01)

Some pharmacogenetic aspects of the <i>ABCB1</i> gene in lopinavir / ritonavir concentration variability in children with HIV infection: A pilot study
by: A. Yu. Sambyalova, et al.
Published: (2022-12-01)

No association of rs1065852 and rs3892097 polymorphisms gene CYP2D6 with treatment resistant schizophrenia
by: D. N. Sosin, et al.
Published: (2019-12-01)

PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS
by: B. I. Kantemirova, et al.
Published: (2021-05-01)

Adverse effects of antiseizure medications: a review of the impact of pharmacogenetics and drugs interactions in clinical practice
by: Michela De Bellis, et al.
Published: (2025-07-01)

Organo-protective effects of quinapril: pharmacogenetic aspects
by: D. A. Sychev, et al.
Published: (2011-04-01)

EFFECT OF GENES SLCO1B1 AND MDR1 POLYMORPHISM ON ATORVASTATIN PHARMACOKINETICS AND PHARMACODYNAMICS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: RESULTS OF PILOT PHARMACOGENETICS STUDY
by: A. V. Semenov, et al.
Published: (2016-01-01)

Pharmacogenetic exploration of buprenorphine and related metabolites in umbilical cord blood
by: Amelia Monfared, et al.
Published: (2025-12-01)

Pharmacogenetic Aspects of Postoperative Anesthesia with Ketoprofen in Cardiac Surgery Patients
by: T. E. Morozova, et al.
Published: (2021-11-01)

A Model for Predicting the Risk of Developing Drug-Induced Liver Injury During Therapy with Favipiravir
by: Yu. V. Shevchuk, et al.
Published: (2025-02-01)

THE COMPARATIVE EFFICACY OF PERSONALIZING THERAPY WITH ANTICONVULSANTS AND ANTIPSYCHOTICS ON THE BASIS OF PHARMACOGENETIC TESTING
by: T. V. Dokukina, et al.
Published: (2016-08-01)

Analysis of CYP2D6 Gene Variant Frequencies in Iranian Population
by: Mahsa Hokmabadi, et al.
Published: (2025-05-01)

The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study
by: Irina A. Mednova, et al.
Published: (2025-06-01)

Wet granulation method in the technology of 6,8-dimethyl-2-piperidinomethyl-2,3-dihydrothiazolo[2,3-F]xanthine tablets, which increases the detoxifying function of the liver
by: A. I. Petrakov, et al.
Published: (2025-06-01)

The Effect of Polymorphisms in the CYP2D6 and CYP2C9 Genes on the Clinical Efficacy of Tramadol and Ketorolac When Using the Accelerated Recovery Protocol in Patients With Uncomplicated Acute Calculous Cholecystitis Who Underwent Cholecystectomy
by: A. A. Muradyan, et al.
Published: (2020-10-01)

Pharmacokinetics and Pharmacogenetics of Apixaban
by: A. V. Savinova, et al.
Published: (2020-11-01)

PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION
by: A. V. Kryukov, et al.
Published: (2017-07-01)

PHARMACOGENETIC TESTING OPPORTUNITIES IN CARDIOLOGY BASED ON EXOME SEQUENCING
by: N. V. Shcherbakova, et al.
Published: (2015-09-01)

Mechanisms of development of antipsychotic-induced metabolic disorders: pharmacogenetic aspect
by: R. F. Nasyrova, et al.
Published: (2018-01-01)

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
by: N. A. Shatalova, et al.
Published: (2023-11-01)

Clinical Pharmacology Aspects of Some Tocolytic Drugs Used in Pregnant Women at Risk of Preterm Birth
by: E. A. Sоkоvа, et al.
Published: (2019-09-01)

ASPECTS OF LIPID-LOWERING THERAPY WITH ATORVASTATIN IN PATIENTS WITH MYOCARDIAL INFARCTION FROM THE PERSPECTIVE OF PERSONALIZED MEDICINE
by: M. V. Solodun, et al.
Published: (2015-09-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants
by: K. B. Mirzaev, et al.
Published: (2020-11-01)

APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY
by: D. A. Sychev, et al.
Published: (2015-09-01)

Therapeutic drug monitoring vs. pharmacogenetic testing in the context of elevated olanzapine concentrations and prior clozapine intolerability: a case study
by: Farah Khorassani, et al.
Published: (2024-12-01)

VARFARIN DOSE REGIME APPROACHS BASED ON PHARMACOGENETICS TEST RESULTS: REAL POSSIBILITY TO OPTIMIZE THE PHARMACOTHERAPY
by: D. A. Sychev, et al.
Published: (2015-12-01)

Pharmacogenetic testing of allelic variants of the CYP2D6 gene in hormone positive breast cancer
by: L. N. Lyubchenko, et al.
Published: (2017-10-01)

EXPERIENCE GENERIC VALPROATE IN ADULTS WITH FOCAL EPILEPSY (RESULTS THE OBSERVATIONS IN MOSCOW HEALTH FACILITY OUTPATIENT NETWORK)
by: I. Yu. Artemova, et al.
Published: (2016-05-01)

Effect of triftazin (trifluoperazine) on the symptoms of autism spectrum disorders in rats with fetal valproatate syndrome
by: I. G. Kapitsa, et al.
Published: (2017-07-01)

Assessing the genetic profile of cytochrome P450 and glutathione S-transferases of patients diagnosed with acute myeloid leukemia
by: Gilmar de Andrade França, et al.
Published: (2025-04-01)

Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review
by: A. V. Kryukov, et al.
Published: (2022-12-01)

APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA
by: D. A. Sychev, et al.
Published: (2015-09-01)

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE
by: A. I. Akhmetova, et al.
Published: (2017-12-01)

FREQUENCY CHARACTERISTICS OF THE GENES OF THE SECOND PHASE OF DETOXIFICATION OF XENOBIOTICS IN WOMEN OF rUSSIAN AND BURYAT ETHNIC GROUPS
by: E. E. Stupko, et al.
Published: (2012-05-01)

PREVALENCE OF POLYMORPHOUS LOCUS 681G>A OF CYP2C19 GENE IN RUSSIAN POPULATION
by: T. A. Bairova, et al.
Published: (2014-11-01)

CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01)

Possibilities of Predicting Methotrexate-associated Toxicity in Oncohematology Based on Molecular Genetic Testing Methods
by: Zarui K. Simavonyan, et al.
Published: (2024-11-01)

A description of sodium valproate, lamotrigine and levetiracetam consumption in the Western Cape public sector
by: Nicole Keuler, et al.
Published: (2022-06-01)